AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00949442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: tablets of 1 and 2 mg
Study NCT00949442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin [NPH]
Description: 100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
Study NCT03548077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWERPLAY
Description: All men from participating worksites are invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)
Study NCT00900939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet
Description: Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
Study NCT00900939 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
Study NCT02959502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receive tDCS+CR
Description: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
Study NCT02959502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitate tDCS + CR
Description: Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
Study NCT03368807 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring
Description: Commercially available
Study NCT03368807 — intervention group
Intervention type: DRUG
Intervention: Insulin Lispro
Description: As prescribed.
Study NCT01035138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semagacestat
Description: 140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
Study NCT03641976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-FOLFOXIRI
Description: Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV
Study NCT03641976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (A-FOLFOX/A-FOLFIRI)
Description: Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV
Study NCT01171378 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ofatumumab
Description: 1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks
Study NCT01550133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learned: Non-nutritive beverage to Non-nutritive beverage
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.
Study NCT01550133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learned: Nutritive solid to Nutritive solid
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
Study NCT01550133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learned: Nutritive beverage to Nutritive beverage
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
Study NCT01550133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Non-nutritive solid to Nutritive solid
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
Study NCT01550133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Nutritive beverage to Non-nutritive beverage
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.
Study NCT01550133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Non-Nutritive solid to Non-nutritive solid
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
Study NCT01550133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Non-nutritive beverage to Nutritive beverage
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
Study NCT01550133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Not Learned: Non-Nutritive solid to Non-Nutritive Solid
Description: For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
Study NCT01990326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XAF5 Gel
Study NCT01990326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Study NCT02866656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional conservative treatment
Description: Treatment last for 4 weeks, three times a week,
Study NCT02866656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic ultrasound
Description: Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
Study NCT00843492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium
Description: After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg \[0.5mL\] (1.5 mg \[0.3mL\] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
Study NCT00843492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
Study NCT02833896 — intervention group
Intervention type: GENETIC
Intervention: surgery
Study NCT02683629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTCELL Implantation
Description: NTCELL Implantation
Study NCT02683629 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Description: Sham Surgery
Study NCT03651141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic Sliding
Description: Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.
Study NCT03651141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Decompression
Description: For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
Study NCT03651141 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diathermy
Description: The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
Study NCT00800358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalitol
Description: oral paricalcitol variable daily dosing based on intact PTH level for 6 months
Study NCT00800358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: oral calcitriol variable daily dosing based on intact PTH level for 6 months
Study NCT02343861 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored leaflet group
Description: Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
Study NCT02343861 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
Study NCT01583881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal denervation
Description: Renal denervation
Study NCT00102323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
Study NCT00102323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Study NCT03289078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa Treatment
Description: The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
Study NCT01712711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.pylori eradication
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
Study NCT01200329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2775 mg/m2 by vein over about 3 hours on days -8 and -3.
Study NCT02064348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Solution for s.c. injection or tablets for oral administration
Study NCT02064348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Solution for s.c. injection or tablets for oral administration
Study NCT02064348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Tablets for oral administration
Study NCT02064348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: Tablets for oral administration
Study NCT03277092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeinViewer®
Description: Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
Study NCT01200329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5.
Study NCT01200329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein over about 30 minutes on days -3 and -2.
Study NCT01200329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.
Study NCT01200329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
Study NCT03400449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video counseling
Description: Video counseling
Study NCT03400449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conversational counseling
Description: Conversational counseling
Study NCT03642990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Capsule
Study NCT02851602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02851602 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Study NCT01620645 — intervention group
Intervention type: RADIATION
Intervention: CT scan and PA chest X-ray
Description: All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK.
Study NCT02952651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse oximeter
Description: When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
Study NCT02499016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic single-incision laparoscopic appendectomy
Description: the approach of appendectomy
Study NCT02499016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprapubic single-incision laparoscopic appendectomy
Description: the approach of appendectomy
Study NCT03277092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The blood drawing is performed traditionally
Study NCT06064539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Tablet, taken orally
Study NCT00688441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal CO2
Description: Twice daily during the 14 day Treatment Period
Study NCT00688441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of the study drug dispenser at the same frequency as the active arm
Study NCT04005040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile X-ray
Description: Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
Study NCT04005040 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Mobile X-ray
Description: Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
Study NCT02981979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leflunomide 10mg Tab
Description: 20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).
Study NCT02981979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide 10mg Tab
Description: 20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).
Study NCT02981979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone Acetate
Description: basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）
Study NCT02981979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone Acetate
Description: basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）
Study NCT02981979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: used in control group during the induced remission therapy for 24 weeks.
Study NCT01268995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
Study NCT01268995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
Study NCT04400266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone 15mg once daily
Study NCT04400266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mealatonin
Description: Melatonin 3mg once nightly
Study NCT01689597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Comparison of different dosages of drug
Study NCT01689597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03456245 — intervention group
Intervention type: DEVICE
Intervention: Vision device validation
Description: Group members had their vision tested with the following devices/methods: Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
Study NCT04078009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aquagen
Description: To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.